Dr. Francesco Zappa
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Baty F, Jörger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med 2017; 15:66.
Mar 30, 201724h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Mar 30, 2017J Transl Med 2017; 15:66
Baty Florent, Jörger Markus, Früh Martin, Klingbiel Dirk, Zappa Francesco, Brutsche Martin
High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA)
Baty F, Klingbiel D, Zappa F, Brutsche M. High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA). J Biomed Inform 2015
Oct 19, 2015High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA)
Oct 19, 2015J Biomed Inform 2015
Baty Florent, Klingbiel Dirk, Zappa Francesco, Brutsche Martin
Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial)
Franzini A, Zappa F, Klingbiel D, Grigoriu B, Betticher D, Droege C, Oliver D, Macovei I, Baty F, Brutsche M. Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial). Clin Cancer Res 2015
Apr 28, 2015Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial)
Apr 28, 2015Clin Cancer Res 2015
Franzini Anca, Zappa Francesco, Klingbiel Dirk, Grigoriu Bogdan D, Betticher Daniel, Droege Cornelia, Oliver Dürr, Macovei Ina I, Baty Florent, Brutsche Martin
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
Sep 10, 2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Sep 10, 2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2012; 79:59-64.
Nov 1, 2012VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Nov 1, 2012Lung Cancer 2012; 79:59-64
Gautschi Oliver, Stahel Rolf, Carbone David, Na Kyung-Jae, Hsu Schmitz Shu-Fang, Bubendorf Lukas, Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Roder Joanna, Grigorieva Julia, Roder Heinrich, Peters Solange, Crowe Susanne, Dingemans Anne-Marie, Smit Egbert